Clinical Trials Logo

Clinical Trial Summary

Prevora is an antiseptic medication and dental treatment approved by Health Canada for reducing root decay (cavities) in adults at high risk of dental decay. An antiseptic kills germs and harmful bacteria. Prevora is applied to the teeth and gumline by a medical professional, takes about 10 minutes and is painless. Participating site(s) have a homecare program and usual care includes offering patients home care services before discharge from the hospital for some chronic diseases. Usual care includes home visits by a nurse and or personal support worker (PSW). The aim of this study is to explore the effectiveness, health benefits and feasibility of delivering preventive oral healthcare with Prevora, during a homecare visit by a nurse or PSW. All consenting and eligible subjects will continue with their usual care with the homecare program. The study is 5 months long. Subjects will have a Prevora treatment applied by the homecare nurse or PSW on Day 1, 14 days, 3 months and 4 months. The study includes several follow up visits which will be conducted in the patient's home and or by telephone or videoconferencing if needed. Oral exams, lab tests and subject completed questionnaires will be collected for the study. Changes in medications and any possible side effects will also be monitored during the study.


Clinical Trial Description

Poor oral health and specifically, inflammation of the gums is linked to respiratory problems, heart problems and inflammation through the body. Worsening oral health and inflammation of the gums occurs often in patients with chronic diseases who are hospitalized and often continues after discharge from the hospital. This can make health recovery more difficult for the patient. This is a 5 month, prospective, single-arm, open-label, observational and feasibility, phase IV trial evaluating the efficacy and safety of Prevora and is focused on the integration of a preventive oral healthcare service into a hospital-based home healthcare program involving high-risk adults with COPD or CHF or on dialysis, and possibly other chronic metabolic conditions, which make the patient suitable for entry into a home care program. This study will be centrally coordinated by the Research Institute at St Joes and conducted in the homes of consenting and eligible participants in the greater Hamilton, Ontario area. Approximately 30 subjects will be enrolled in the study which is defined as starting the investigational product. All subjects will continue to receive the usual care that is provided as part of the respective home care program. After signed consent is obtained, subject screening and eligibility assessments will begin. Once a subject is confirmed to be eligible for study participation, investigational product treatment applications and study visits will be scheduled starting with Day 1. Follow up visits will occur 14 days, 1, 3, 4 and 5 months after Day 1. A delegated and trained homecare nurse or PSW will apply the investigational product during the study visits conducted on day 1, day 14, 3 and 4 months. Study visits will be scheduled at the same time as a standard of care (SOC) home visit or as a study visit only, independent of a SOC home visit. Study visits include evaluation of study outcomes/endpoints, subject completed questionnaires and measuring compliance. Changes in medications and any possible side effects will also be monitored during the study. Data will be captured in the case report form (CRF). To qualify, men and women must be enrolled in the home healthcare services program. All participants will receive the study intervention (Prevora) and be followed for 5 months. This study aims to demonstrate that in subjects who receive home healthcare visits and have COPD and/or CHF or on dialysis, and with moderate to severe forms of chronic oral inflammation, the investigational product (Prevora) will significantly decrease oral inflammation over time. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06158633
Study type Observational
Source CHX Technologies Inc.
Contact Suzana Damjanovic
Phone 365-833-8140
Email DentalStudy@stjoes.ca
Status Not yet recruiting
Phase
Start date December 2023
Completion date October 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05031013 - Trace Elements Concentration in Dialysis
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Completed NCT01685372 - Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults Phase 2
Active, not recruiting NCT01394770 - Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients Phase 4
Completed NCT00506441 - A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Phase 3
Completed NCT00537979 - Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Phase 4
Completed NCT05415969 - CKD-aP Among Adults on Dialysis in Switzerland
Recruiting NCT04024007 - Determination of Citrate Clearance Used in Regional Anticoagulation of Continuous Venous Hemofiltration Circuits
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Active, not recruiting NCT01693263 - Outcome of BCF Access in Hemodialysis Patients
Completed NCT01421771 - Blood Pressure in Dialysis Patients N/A
Active, not recruiting NCT01065389 - Resistance Training in Intradialysis Patients Phase 2
Completed NCT00544492 - Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients Phase 4
Completed NCT03910426 - Prognostic Determinants of Survival and Quality of Life in Prevalent End-stage Kidney Disease Patients
Completed NCT04565522 - Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers
Completed NCT04667741 - Post-dialysis Recovery Time and Affecting Factors Between Turkey and Portugal
Completed NCT04655989 - A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System N/A
Completed NCT05125848 - Clinical Evaluation of the CM-1500 During Hemodialysis N/A
Completed NCT04633915 - Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.